- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07729046
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease control for participants with metastatic endocrine-resistant ER+/HER2-negative breast cancer. Neratinib is already approved for the treatment of HER2-postive breast cancers. The study will also learn about the safety of adding this drug to standard of care treatments. The main questions it aims to answer are:
- Does adding neratinib to standard of care systemic therapy improve disease control for patients with metastatic hormone-driven breast cancer that is resistant to endocrine therapy?
- What side effects do participants have when adding neratinib to standard of care therapy? Researchers will compare standard of care endocrine therapy regimens with and without neratinib to see if neratinib improves control of treatment-resistant metastatic breast cancer that has continued to progress while eon first line endocrine therapy.
Participants will:
- Take standard of care endocrine therapy for metastatic endocrine-resistant breast cancer as determined by their medical oncologist or standard of care therapy with neratinib daily
- Visit the clinic every 3 months for checkups, tests and imaging studies
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Asona Lui, MD, PhD
- Telefoonnummer: 858-822-4319
- E-mail: ajlui@health.ucsd.edu
Studie Contact Back-up
- Naam: Alyssa Beck, MD
- Telefoonnummer: 858-657-7000
- E-mail: a4beck@health.ucsd.edu
Studie Locaties
-
-
California
-
La Jolla, California, Verenigde Staten, 92037
- UC San Diego Health Moores Cancer Center
-
Contact:
- Sauntee Braddock
- Telefoonnummer: 858-534-8248
- E-mail: sbraddock@health.ucsd.edu
-
Hoofdonderzoeker:
- Asona Lui, MD, PhD
-
Onderonderzoeker:
- Alyssa Beck, MD
-
Onderonderzoeker:
- Svasti Haricharan, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Female over the age of 18 at the time of study enrollment
- Not pregnant, planning to become pregnant or breast feeding
- Metastatic ER+/HER2- breast cancer that has progressed on 1st line therapy including endocrine therapy +/- CDK4/6 inhibitors
- At least one metastatic lesion visible on imaging (including FDG-PET)
- At least one metastatic lesion must be biopsied and confirmed ER+ and HER2- by immunohistochemistry within 6 months of study screening (HER2 equivocal disease will be confirmed HER2- by FISH)
- Tumors must be MLH1-low defined by <50% tumor cells positive for nuclear MLH1 expression on immunohistochemistry
- Standard of care next line endocrine therapy can include any endocrine therapy
- Performance status ECOG > 3
- Life expectancy > 1 year
- Ability to get serial imaging studies
Exclusion Criteria:
- History of concurrent use of other HER2-targeted therapy
- Concurrent use of other targeted systemic therapy
- History of other cancers other than non-melanoma skin cancer
- Actionable mutations on tumor genomic sequencing will be ineligible, and those participants encouraged to proceed with the relevant targeted therapy
- Participants where there is not at least one imaging apparent lesion that has not been treated with prior targeted therapy (for example palliative radiation or cryoablation)
- Contraindications to Neratinib use including allergy or hypersensitivity
- Baseline grade 3+ diarrhea
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Standard of Care
Standard of Care 2nd or 3rd line endocrine therapy with or without CDK4/6 inhibitor
|
Endocrine therapy with out without CDK4/6 inhibitor
Endocrine therapy with or without CDK 4/6 inhibitor
|
|
Experimenteel: Stanard of Care + Neratinib
Standard of Care 2nd or 3rd line endocrine therapy with or without CDK4/6 inhibitor + Neratinib
|
Endocrine therapy with or without CDK 4/6 inhibitor
Neratinib 120mg daily for 1 week, 160mg daily for 1 week and then 240mg daily thereafter
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Median Progression-Free Survival
Tijdsspanne: From enrollment through study completion, an average of 1 year.
|
From enrollment through study completion, an average of 1 year.
|
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Tijdsspanne: From enrollment through study completion, an average of 1 year.
|
Adverse events will be quantified using the CTCAE v4.0 every 3 months
|
From enrollment through study completion, an average of 1 year.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Asona Lui, MD, PhD, UC San Diego
Publicaties en nuttige links
Algemene publicaties
- Mazumder A, Dewitt J, Oropeza E, Punturi N, Lozano D, Raghunathan M, Piscitelli J, Sajjadi E, GueriniRocco E, Venetis K, Ivanova M, Mane E, Dercole M, Concardi A, Fusco N, Manhart C, Bainbridge M, Haricharan S. Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence. Nat Commun. 2025 Dec 10;17(1):564. doi: 10.1038/s41467-025-67257-8.
- Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, Fusco N. Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell Int. 2021 May 17;21(1):266. doi: 10.1186/s12935-021-01976-y.
- Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clin Cancer Res. 2018 Oct 1;24(19):4887-4899. doi: 10.1158/1078-0432.CCR-17-3702. Epub 2018 May 23.
- Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.
- Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S. Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nat Commun. 2021 May 19;12(1):2940. doi: 10.1038/s41467-021-23271-0.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Huidziektes
- Borst ziekten
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Azoles
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Steroïden
- Verbindingen met gefuseerde ring
- Benzeenderivaten
- Nitriles
- Estradiol
- Woest
- Estranes
- Estradiol -congeners
- Gonadale steroïde hormonen
- Gonadale hormonen
- Triazoles
- Stilbenen
- Benzylideenverbindingen
- Fulvestrant
- Anastrozol
- Tamoxifen
- exemestane
- neratinib
Andere studie-ID-nummers
- BC250474 (Ander subsidie-/financieringsnummer: Congressionally Designated Medical Research Program (CDMRP), US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY)
- 813310 (Andere identificatie: UC San Diego Institutional Review Board (IRB))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .